Advertisement

Advertisement

AACR Annual Meeting 2024

Pancreatic Cancer

Is a Test for Early Detection of Pancreatic Cancer on the Horizon?

An investigational noninvasive exosome-based liquid biopsy shows potential for early detection of pancreatic cancer, an important unmet need, according to research presented at the American Associatio...

Kidney Cancer
Immunotherapy

CRISPR-Edited, Off-the-Shelf CAR T-Cell Therapy Shows Proof of Concept in Renal Cell Carcinoma

Evidence from a small early trial called COBALT-RCC provides proof of concept for use of an allogeneic off-the-shelf CD70-targeted chimeric antigen receptor (CAR) T-cell therapy called CTX130 in patie...

Multiple Myeloma

Linvoseltamab Achieves High Response Rates in Relapsed or Refractory Myeloma

The investigational bispecific antibody linvoseltamab (targeting B-cell maturation antigen [BCMA] and CD3) achieved high response rates with acceptable safety in heavily pretreated patients with relap...

Gastroesophageal Cancer

Bispecific Antibody Plus Chemotherapy Improves Survival in Patients With Gastric or Gastroesophageal Junction Cancer

Treatment with the first-in-class PD-1/CTLA-4 bispecific antibody cadonilimab plus XELOX (capecitabine, oxaliplatin) chemotherapy demonstrated a survival advantage for patients with advanced gastric o...

Breast Cancer

Selective Targeting of PARP1 in Early-Phase Study Shows Activity in Breast Cancer

Saruparib, a first-in-class PARP1-­selective inhibitor, was reported to have favorable safety and anticancer activity in heavily pretreated patients with breast cancer harboring homologous recombinati...

lung cancer

Pasi A. Jänne, MD, PhD, on NSCLC, Osimertinib, Chemotherapy: Update From FLAURA2

Pasi A. Jänne, MD, PhD, of Dana-Farber Cancer Institute, discusses an exploratory analysis from the FLAURA2 study, which indicates that baseline levels of plasma EGFR mutation may be prognostic and pr...

breast cancer

Kelly K. Hunt, MD, on Breast Cancer and Neoadjuvant Therapy: Expert Commentary

Kelly K. Hunt, MD, of The University of Texas MD Anderson Cancer Center, discusses the benefits to patients with neoadjuvant therapy in advanced, inoperable breast cancer, for whom this treatment work...

Gynecologic Cancers

AI Analysis of Cell-Free DNA Fragments and Protein Biomarkers for Noninvasive Detection of Ovarian Cancer

A blood-based, machine learning assay that combines cell-free DNA (cfDNA) fragmentomes and protein biomarkers was able to differentiate patients with ovarian cancer from healthy controls at a high spe...

Colorectal Cancer

Adagrasib Plus Cetuximab: Potential Option for KRAS G12C–Mutated Colorectal Cancer

Although KRAS was once considered an untargetable mutation, KRAS inhibitors are now approved for the treatment of KRAS-mutated non–small cell lung cancer (NSCLC) and are emerging as a potential option...

Gynecologic Cancers

Blood-Based Machine-Learning Assay May Noninvasively Detect Early Ovarian Cancer

Ovarian cancer is the eighth most-common cancer among women globally, and the eighth most-common cause of death from cancer worldwide. In the United States alone, in 2023, there were nearly 20,000 new...

Prostate Cancer
Issues in Oncology

Educational Videos May Encourage Prostate Cancer Screening Among Black Patients

Use of culturally sensitive educational videos may boost knowledge and decrease uncertainty regarding prostate cancer and screening among Black individuals, according to new findings presented by Jone...

Solid Tumors
Genomics/Genetics

BAP1 Mutations May Increase Susceptibility to Asbestos-Induced Malignant Mesothelioma

Researchers have shown that even minimal exposure to chrysotile asbestos may increase susceptibility to the development of malignant mesothelioma in mice with BAP1 germline mutations, according to new...

Pancreatic Cancer

An Exosome-Based Liquid Biopsy for Early Detection of Pancreatic Cancer

An investigational exosome-based liquid biopsy accurately detected 97% of stage I to II pancreatic cancers when combined with the biomarker CA 19-9, according to research presented at the American Ass...

Prostate Cancer
Genomics/Genetics

Proteogenomic Signatures May Help Identify Risk of Prostate Cancer Progression in Certain Populations

Certain proteogenomic signatures in the prostate cancers of men of African and European ancestries were associated with higher risk of metastasis and/or recurrence of the disease, according to a study...

Issues in Oncology

AACR Inaugurates New Leadership

The members of the American Association for Cancer Research (AACR) elected a new 2024 to 2025 President and President-Elect at the AACR’s Annual Business Meeting of Members during the AACR Annual Meet...

Breast Cancer
Genomics/Genetics

PARP1-Selective Inhibitor in HRR-Deficient Breast Cancer

The novel poly-ADP ribose polymerase-1 (PARP1)-selective inhibitor saruparib demonstrated early efficacy and a favorable safety profile in patients with homologous recombination repair (HRR)-deficient...

Head and Neck Cancer

Investigational Personalized Vaccine in Resected Head and Neck Cancers

TG4050, a personalized neoantigen vaccine, induced tumor-specific immune responses and led to low rates of disease relapse in patients with surgically resected human papillomavirus (HPV)-negative head...

CNS Cancers

ATM Kinase Inhibitor Plus Radiotherapy for Patients With Glioblastoma

AZD1390, an ataxia telangiectasia mutant (ATM) kinase inhibitor, demonstrated a manageable safety profile in patients with both recurrent and newly diagnosed glioblastoma when given in combination wit...

Colorectal Cancer

Adagrasib Plus Cetuximab in KRAS G12C–Mutated Colorectal Cancer

The combination of the KRAS G12C inhibitor adagrasib and the anti-EGFR antibody cetuximab showed clinical activity and promising survival outcomes in a cohort of patients with metastatic, heavily pret...

Prostate Cancer
Immunotherapy

Biologic Drug-Device Combination Immunotherapy in Metastatic Prostate Cancer

SYNC-T—an investigational therapy that combines a device-induced vaccination at the tumor site with an intratumoral infusion of a multitarget biologic drug—led to numerous clinical responses in patien...

Pancreatic Cancer

Immune Response to Investigational RNA Vaccine for Pancreatic Cancer Continues to Correlate With Clinical Benefit

An adjuvant treatment regimen that included autogene cevumeran, an investigational individualized neoantigen-specific mRNA vaccine, induced durable and functional T-cell responses that were associated...

Gastroesophageal Cancer
Gastrointestinal Cancer
Immunotherapy

Bispecific Immune Checkpoint Inhibitor Improves Survival in Patients With Gastric Cancer, Regardless of PD-L1 Status

The PD-1/CTLA-4 bispecific antibody cadonilimab plus chemotherapy improved progression-free and overall survival in patients with untreated, HER2-negative, locally advanced or metastatic gastric or ga...

Skin Cancer
Immunotherapy

RP1 Immunotherapy in Solid Organ Transplant Recipients With Skin Cancer

A novel oncolytic immunotherapy may show antitumor activity in solid organ transplant recipients with skin cancer, according to new findings presented by Migden et al at the American Association for C...

Kidney Cancer
Immunotherapy

Novel CAR T-Cell Therapy May Show Benefit in Patients With Advanced Clear Cell Renal Cell Carcinoma

The CD70-targeted allogeneic chimeric antigen receptor (CAR) T-cell therapy CTX130 may be effective in patients with advanced clear cell renal cell carcinoma, according to findings presented by Srour ...

Gynecologic Cancers
Immunotherapy

Mirvetuximab Soravtansine Plus Pembrolizumab in Patients With Endometrial Cancer Subtype

The combination of the antibody-drug conjugate mirvetuximab soravtansine-gynx and the immune checkpoint inhibitor pembrolizumab showed notable activity in patients with recurrent or persistent microsa...

Hepatobiliary Cancer
Immunotherapy

Can a Personalized Antitumor Vaccine Plus Pembrolizumab Improve Outcomes in Hepatocellular Carcinoma?

Adding a personalized antitumor vaccine to the PD-1 inhibitor pembrolizumab may be safe and about twice as effective at shrinking tumors in patients with hepatocellular carcinoma compared with pembrol...

Issues in Oncology

Accelerated Aging May Be a Risk Factor for Early-Onset Cancers in Younger Generations

According to recent studies, the incidence of early-onset cancers—often defined as those diagnosed in individuals younger than age 50—is on the rise, and not just in the United States but globally as ...

Issues in Oncology

Fewer Than Half of Drugs Granted Accelerated Approval Demonstrated Benefit Within 5 Years

In 1992, the U.S. Food and Drug Administration (FDA) instituted its Accelerated Approval regulations, which allow drugs that treat serious conditions and fill an unmet need to be approved early based ...

Advertisement

Advertisement




Advertisement